inside the quickly evolving discipline of oncology research, exact and productive mutation screening is crucial for developing targeted therapies. The KRAS companies Platform performs a pivotal role On this landscape by presenting in depth solutions for KRAS mutation profiling and analysis. KRAS mutations, present in around 95% of RAS-relevant onco